Clinical Trial Update: Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing safety and immune response of vicriviroc in combination regimens for ART-experienced HIV-infected children and adolescents.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Vicriviroc (MK-7690)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-02-01